Anika Therapeutics Inc
Closed
SectorHealthcare
13.35 -2.41
Overview
Share price change
24h
Min
13.16
Max
13.66
Income | -3.6M -311K |
|---|---|
Sales | -2M 31M |
EPS | -0.01 |
Profit margin | -1.017 |
Employees | 235 |
EBITDA | -5.6M -712K |
Recommendations | Buy |
|---|---|
12 Months Forecast | +66.55% upside |
Market Cap | -65M 195M |
|---|---|
Previous open | 15.76 |
Previous close | 13.35 |
Anika Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Anika Therapeutics Inc Forecast
Price Target
By TipRanks
66.55% upside
12 Months Forecast
Average 23 USD 66.55%
High 23 USD
Low 23 USD
Based on 2 Wall Street analysts offering 12 month price targets forAnika Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
